Skip to content
medxy logo Medxy AI
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • facebook.com
  • twitter.com
  • t.me
  • instagram.com
  • youtube.com
Subscribe
  • Home
  • p16
Radiotherapy Interruptions in Head and Neck Cancer Raise Risk of Locoregional Failure and Death — Impact Depends on p16 Status and Stage
Posted innews Oncology Otorhinolaryngology

Radiotherapy Interruptions in Head and Neck Cancer Raise Risk of Locoregional Failure and Death — Impact Depends on p16 Status and Stage

Posted by MedXY By MedXY 12/08/2025
Secondary analysis of three RTOG/NRG trials shows radiotherapy interruptions are associated with higher locoregional failure and worse overall survival in head and neck cancer, with larger absolute harms in p16‑negative and high‑stage disease.
Read More
HPV-Positive Oropharyngeal Cancer Retains a Strong Survival Advantage After Surgery in Patients Aged ≥70
Posted innews Oncology Otorhinolaryngology

HPV-Positive Oropharyngeal Cancer Retains a Strong Survival Advantage After Surgery in Patients Aged ≥70

Posted by MedXY By MedXY 11/21/2025
In a multi-center cohort of 345 surgically treated patients aged 70 or older with tonsil or base‑of‑tongue SCC, p16 positivity was associated with substantially better 5‑year overall and disease‑free survival compared with p16‑negative tumors.
Read More
  • Adherence to the Planetary Health Diet Index Significantly Lowers MASLD Risk: A Global and Individual-Level Analysis
  • The Double-Win Diet: How the Planetary Health Index Protects Your Liver and the Earth
  • Healthy Nordic Diet vs. Anti-Lipogenic High-Fat Diet: Superior Cardiometabolic Outcomes in the NAFLDiet Trial
  • Beyond the Oral Cavity: Probiotic Adjuncts in Periodontitis Yield Systemic Glycemic Benefits for Diabetic Patients
  • Beyond the High-Protein Hype: Why Moderate Diets May Be the Secret to Reversing Prediabetes
  • About us
  • Contact us
  • MedXY story
  • Privacy Policy
  • Subscribe Now!
  • 账号

  • English
  • 日本語
  • Tiếng Việt
  • 中文

aging Alzheimer's disease artificial intelligence atrial fibrillation biomarkers breast cancer Cardiology cardiovascular disease cardiovascular health cardiovascular risk chronic kidney disease clinical trial clinical trials critical care depression diabetes epidemiology exercise health heart failure Hypertension immunotherapy inflammation MASLD mental health metformin Mortality multiple myeloma nutrition obesity older adults Pediatrics Physical Activity Pregnancy prevention prostate cancer public health randomized clinical trial randomized trial SGLT2 inhibitors stroke targeted therapy type 2 diabetes weight loss women's health

Your health, we care

Copyright 2026 — Medxy AI. All rights reserved.
Scroll to Top
Sign in